{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:43:41Z","timestamp":1649209421320},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JADPRO"],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:p>With conference reporting provided by The ASCO Post, Amber B. Koehler, PA-C, MS, of Mayo Clinic, evaluates data on BTK inhibitors; fixed-duration, first-line treatment with ibrutinib plus venetoclax; and a novel oral BCL2 antagonist for patients with CLL. P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, reviews data on a front-line therapy for patients with Ph+ acute lymphoblastic leukemia and brexucabtagene autoleucel, an anti-CD19 CAR T-cell therapy. Donna Catamero, ANP-BC, OCN\u00ae, CCRC, of Mount Sinai Hospital, reflects on findings on a BCMA-directed CAR T-cell therapy and a bispecific monoclonal antibody for patients with multiple myeloma.<\/jats:p>","DOI":"10.6004\/jadpro.2021.12.6.11","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T18:42:27Z","timestamp":1631040147000},"source":"Crossref","is-referenced-by-count":0,"title":["Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner"],"prefix":"10.6004","volume":"12","author":[{"given":"Amber","family":"B. Koehler, PA-C, MS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Andrew","family":"Allred, MS, PA-C","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Catamero, ANP-BC, OCN, CCRC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","published-online":{"date-parts":[[2021,8,1]]},"container-title":["Journal of the Advanced Practitioner in Oncology"],"original-title":[],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T18:42:42Z","timestamp":1631040162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.advancedpractitioner.com\/issues\/volume-12,-number-6-(aug-2021)\/hematologic-malignancies-2021-asco-annual-meeting-highlights-for-the-advanced-practitioner.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.6004\/jadpro.2021.12.6.11","relation":{},"ISSN":["2150-0878"],"issn-type":[{"value":"2150-0878","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}